Drug intelligence / Profile preview

OS002

Development stage: Preclinical
Lead developer: OmniSpirant
Modality: Stem Cell Therapies → Cell Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Inhalation

Overview

OS002 is a preclinical-stage therapeutic candidate being developed by OmniSpirant for the treatment of Chronic Obstructive Pulmonary Disease (COPD). It is based on the company's proprietary OmniSome platform, which utilizes bioengineered extracellular vesicles (exosomes) derived from stem cells. These exosomes are designed to deliver therapeutic payloads directly to the lungs, likely via inhalation, to address the underlying pathology of chronic respiratory diseases. While the specific molecular target or payload for OS002 has not been publicly disclosed, the platform aims to leverage the regenerative and anti-inflammatory properties of stem cell-derived exosomes to provide a transformative treatment for COPD.

Beyond the preview

Go deeper on OS002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OS002.

Explore the full profile